Stock Research: Zoetis

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Zoetis

NYSE:ZTS US98978V1035
39
  • Value
    61
  • Growth
    36
  • Safety
    Safety
    42
  • Combined
    31
  • Sentiment
    56
  • 360° View
    360° View
    39
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Zoetis Inc. is a global animal health company focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, and services for animals. They operate in the animal health industry, offering products for companion animals (dogs, cats, horses) and livestock (cattle, poultry, swine, fish, sheep). Zoetis markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia, and South America. In the last fiscal year, the company had a market cap of $68,055 million, profits of $6,542 million, revenue of $9,256 million, and 13800 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 39 (better than 39% compared with alternatives), overall professional sentiment and financial characteristics for the stock Zoetis are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Zoetis. The consolidated Sentiment Rank has a good rank of 56, which means that professional investors are more optimistic about the stock than for 56% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 61 or better than 61% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 42, meaning that the share price of Zoetis is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 36. ...read more

more
Index
Dividends USA
Employee Focus US
Diversity USA
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
42 20 17 25
Growth
36 35 71 83
Safety
Safety
61 46 41 34
Sentiment
56 82 98 84
360° View
360° View
39 28 72 66
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
32 78 67 63
Opinions Change
29 13 44 23
Pro Holdings
n/a 76 89 84
Market Pulse
87 95 91 74
Sentiment
56 82 98 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
42 20 17 25
Growth
36 35 71 83
Safety Safety
61 46 41 34
Combined
31 9 28 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
53 34 28 22
Price vs. Earnings (P/E)
18 7 7 10
Price vs. Book (P/B)
11 1 1 1
Dividend Yield
82 86 84 86
Value
42 20 17 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
44 53 62 39
Profit Growth
39 27 49 62
Capital Growth
53 48 36 64
Stock Returns
18 43 81 91
Growth
36 35 71 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
28 24 19 23
Refinancing
37 18 27 17
Liquidity
89 91 82 79
Safety Safety
61 46 41 34

Similar Stocks

Discover high‑ranked alternatives to Zoetis and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

CF Industries

NYSE:CF
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.